Afatinib plus cetuximab shows promise for EGFR-mutated lung cancer

  • July 31, 2014

Afatinib plus cetuximab demonstrated clinical activity and a manageable safety profile in patients with EGFR-mutant lung cancers with acquired resistance to gefitinib or erlotinib, both with and without T790M mutations, according to findings in an early-phase trial.

“Treatment with erlotinib and gefitinib leads to dramatic tumor regression and has improved survival for patients with EGFR-mutant lung adenocarcinoma,” Yelena Y. Janjigian, MD, assistant attending physician at Memorial Sloan Kettering Cancer Center, said in a press release. “Unfortunately, these cancers invariably acquire resistance to these drugs and the patient’s disease progresses. There are currently no effective therapies for patients in this situation.”

Full Story »

Personalize your page!

Register for Healio to get content tailored to your specialty and areas of interest. It’s FREE and only takes one minute. Register now!

More»
More»
More»
More»
More »
  • Financial Planning
  • RUDZINSKI COLUMN
  • Advice for physicians
  • Be aware of important 2014 IRA updates. Analysis by Certified Financial Planner Ken Rudzinski.
More »
HemOnc Today